Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Grant Cannon¹, Wei Chen ¹, JIncheng Shen ², Neil Accortt ³, David Collier ⁴ and Brian Sauer ¹, ¹Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ²Univeristy of Utah, Salt Lake City, UT, ³Amgen, Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
Abstract Number: 1803 • 2019 ACR/ARP Annual Meeting
Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina
Rodrigo Garcia Salinas¹, Maria Alicia Lazaro ², Santiago Scarafia ³, Alejandra Cusa ², Nieves Capozzi ⁴, Luciana Casalla ⁴, Lucia Zarate ⁴, Maria de la Vega ⁵, Maria Correa ⁶, Gustavo Casado ⁷, Silvia Papasidero ⁸, Oscar Rillo ⁹, Nevil Alejandro Muñoz ¹⁰, Mariana Benegas ¹¹, Karin Kirmayr ¹², Maria Paula Girard Bosch ¹³, Maria Victoria Martire ¹⁴ and Ramiro Gomez ¹⁵, ¹Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ²IARI, Buenos Aires, ³Hospital Municipal "San Cayetano", Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Posadas, Buenos Aires, ⁵CEIM Investigaciones Medicas, Buenos Aires, Argentina, ⁶Consultorios Reumatológicos Pampa, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Hospital Militar Central, Buenos Aires, ⁸Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁹Hospital Pirovano, Buenos Aires, ¹⁰Hospital Ramos Mejia, Buenos Aires, ¹¹Sanatorio Mendez, Buenos Aires, ¹²Hospital Zonal Bariloche, Bariloche, ¹³Instituto Médico Platense, La Plata, ¹⁴Hospital San Martín. Instituto Médico Platense, La Plata, ¹⁵Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The biologics therapies in rheumatoid arthritis (RA) implies a well-known risk of infection. It is of utterly importance to count with predictive models to…
Abstract Number: 2301 • 2019 ACR/ARP Annual Meeting
Profile of Renal Function in Patient Suffering from Rheumatoid Arthritis
Denis Choquette¹, Louis Bessette ², Loïc Choquette Sauvageau ³, Isabelle Ferdinand ³, Boulos Haraoui ³, Frédéric Massicotte ³, Jean-Pierre Pelletier ⁴, Jean-Pierre Raynauld ⁵, Marie-Anaïs Rémillard ³, Diane Sauvageau ³, Edith Villeneuve ⁶ and Louis Coupal ³, ¹Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ²Centre de l'Ostéoporose et de Rhumatologie de Québec, Québec, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal, Montréal, QC, Canada, ⁴University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁶Institut de Recherche en Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Many medications used in the treatment of rheumatoid arthritis (RA) impact renal function. Some of these may be contraindicated in the presence of a…
Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Xanthe ME Matthijssen¹, Ellis Niemantsverdriet ², Thomas Huizinga ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…
Abstract Number: 48 • 2019 ACR/ARP Annual Meeting
Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Maria Luque-Tevar ¹, Patricia Ruiz-Limon ³, Laura Pérez-Sanchez ⁴, Sara Remuzgo-Martínez ⁵, Alejandro Ibañez-Costa ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁶, Maria del Carmen Abalos-Aguilera ¹, Andres Delgado-Campos ⁷, Rafaela Ortega ¹, Raquel López-Mejías ⁵, M Angeles Aguirre ⁸, Alejandro Escudero ⁷, Eduardo Collantes-Estevez ⁶, Miguel A. González-Gay ⁹ and Carlos Perez-Sanchez ¹⁰, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain, Málaga, Spain, ⁴MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain, ⁹Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain, ¹⁰Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: 1. To identify and characterize specific immunological, inflammatory and epigenetic determinants involved in the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients. 2.…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 980 • 2019 ACR/ARP Annual Meeting
Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis
Ana Igea ¹, Tiago Carvalheiro ², Beatriz Malvar Fernandez ², Angela Rodriguez-Trillo ³, Trudy McGarry ⁴, Carmen Conde ⁵, Douglas Veale ⁶, Ursula Fearon ⁷, Africa Gonzalez ¹, Timothy R.D. Radstake ⁸, Kris A. Reedquist ² and Samuel Garcia⁹, ¹Department of Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain, ²Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands, ³laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS)-Hospital Clinico (CHUS), Santiago de Compostela, Spain, ⁴Department of Molecular Rheumatology, Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland, ⁵Laboratorio de Reumatología Experimental y Observacional, y Servicio de Reumatología, Instituto de Investigacion Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain, ⁶EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁸Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Spain
Background/Purpose: The semaphorin family is a large group of proteins initially described in axon guidance. However, semaphorins also play a role in other processes involved…
Abstract Number: 1365 • 2019 ACR/ARP Annual Meeting
Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Clifton Bingham¹, Shelly Kafka ², Shawn Black ³, Stephen Xu ⁴ and Jeffrey Curtis ⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, RI, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Use of PROs to assess health-related quality of life in clinical practice, research studies, and clinical trials in Rheumatoid Arthritis (RA) remains an ongoing…
Abstract Number: 1945 • 2019 ACR/ARP Annual Meeting
Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients
Ankita Singh¹, Harikrishnan Nair ², Vikas Gupta ², Pradeepta Sekhar ², Ramnath Misra ³ and Amita Aggarwal ⁴, ¹Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Methotrexate (MTX) is first line therapy to treat rheumatoid arthritis (RA) patients. However, the response is variable with 50-60% showing response and this variability…
Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez ¹, Naydi Pérez-Ríos ¹, Noelia Rodríguez ¹, Grissel Ríos ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Mark Genovese¹, Kenneth Kalunian ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, YingMeei Tan ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
Abstract Number: 89 • 2019 ACR/ARP Annual Meeting
Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis
Ximei Zhang¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State College of Medicine, Columbus, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Enhanced evidence supports that autoimmune diseases often result from an imbalance between regulatory T cells (Tregs) and interleukin-17-producing T helper (Th17) cells. However, under…
Abstract Number: 522 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
Thierry Sornasse¹, Jeremy Sokolove ¹ and Iain McInnes ², ¹AbbVie Immunology Clinical Development, Redwood City, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
Abstract Number: 981 • 2019 ACR/ARP Annual Meeting
Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models
Hani Manfred Sauermilch¹, Marie-Lisa Hülser ¹, Carina Schreiyäck ¹, Yubin Luo ², Aline Bozec ², Georg Schett ³, Ulf Müller-Ladner ⁴ and Elena Neumann ⁵, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Giessen, Germany, ²Department Clinic of Medicine 3 - Immunology and Rheumatology, University of Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁴Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁵Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Giessen, Hessen, Germany
Background/Purpose: Adipocytokines are bioactive factors mainly produced by adipose tissue and exert many important effects on energy homeostasis as well as immune responses. Osteoarthritis (OA)…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].